The LARGEST human ivermectin cancer study EVER conducted found 84% of cancer patients declared COMPLETE REMISSION, TUMOR SHRINKAGE, or HALTED TUMOR GROWTH.
Our study is now PEER-REVIEWED and PUBLISHED by the International Institute of Anticancer Research.
The tide is turning.
IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION
1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day).
LOW DOSE: ≤ 0.5 mg/kg/day
**Best for:**
- Cancers in remission
- Strong family history or genetic predisposition
- Prophylaxis (preventive)
**Side effects:** No long-term side effects reported.
**Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished.
MEDIUM DOSE: 1.0 mg/kg/day
**Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.).
**Side effects:** No long-term side effects reported.
**Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9.
HIGH DOSE: 2.0 mg/kg/day
**Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers).
**Side effects:** No long-term side effects reported.
**Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared.
VERY HIGH DOSE: ≥ 2.5 mg/kg/day
**Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers.
**Side effects:** Possible short-term & transient visual effects (usually resolve in a few days).
**Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported.
**Quick conversion example (for a 60 kg / 132 lb person):**
- Low: ≤30 mg/day
- Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid)
- High: 120 mg/day
- Very High: ≥150 mg/day
Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary.
Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only.
Share to spread awareness — information is power. 💊 Kindly follow me for daily updates. Thank you.
BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal
84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION.
Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995.
The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.
A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole.
Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability.
At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either:
No evidence of disease (32.8%)
Tumor regression (15.6%)
or Cancer stabilization (36.1%)
Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months.
Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments.
This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential.
With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required.
In the meantime, many cancer patients are exercising their right to try.
@twc_health@McCulloughFund@IIAR_Journals@P_McCulloughMD@DrHarveyRisch@DrKellyVictory@jathorpmfm@drdrew@PeterGillooly@FosterCoulson
The Big Beautiful Bill contains a provision banning state & local governments from regulating AI.
It’s worse than you think.
It would make it easier for corporations to get zoning variances, so massive AI data centers could be built in close proximity to residential areas.
FBI REPORT: TRUMP IS COMPROMISED BY ISRAEL
A declassified FBI report said that FBI informants believe Trump is compromised by Israel, and that his Zionist son-in-law JARED KUSHER was the real power behind the presidency.
Just a reminder of the things we’ve stopped talking about
IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION
1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day).
LOW DOSE: ≤ 0.5 mg/kg/day
**Best for:**
- Cancers in remission
- Strong family history or genetic predisposition
- Prophylaxis (preventive)
**Side effects:** No long-term side effects reported.
**Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished.
MEDIUM DOSE: 1.0 mg/kg/day
**Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.).
**Side effects:** No long-term side effects reported.
**Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9.
HIGH DOSE: 2.0 mg/kg/day
**Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers).
**Side effects:** No long-term side effects reported.
**Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared.
VERY HIGH DOSE: ≥ 2.5 mg/kg/day
**Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers.
**Side effects:** Possible short-term & transient visual effects (usually resolve in a few days).
**Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported.
**Quick conversion example (for a 60 kg / 132 lb person):**
- Low: ≤30 mg/day
- Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid)
- High: 120 mg/day
- Very High: ≥150 mg/day
Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary.
Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only.
Share to spread awareness — information is power. 💊
🚨 EVERY VACCINE BATCH HAD A DIFFERENT FORMULA. THE LOT NUMBERS JUST PROVED IT.
Not a theory. Not an interpretation. A dataset. 12,000 lot numbers. Cross-referenced with VAERS adverse event reports. The correlation is absolute.
A team of researchers — 4 statisticians, 2 pharmacologists, 1 former FDA regulator — published their findings on a decentralized server Wednesday. The paper is 147 pages. Peer review was impossible because no journal would touch it. So they released it directly to the public.
The finding: specific lot numbers produced 4,000% more adverse events than others. Not random variation. Not manufacturing inconsistency. A deliberate, systematic pattern.
⟁
Lot numbers ending in 20A through 20F: near-zero adverse events. Saline. Placebo. Water with a label.
Lot numbers ending in 21K through 21X: moderate adverse events. Fatigue. Myocarditis. Blood clots. Hospitalization rates 300% above baseline.
Lot numbers ending in 22R through 22Z: catastrophic. Stroke. Cardiac arrest. Neurological damage. Death rates 8,100% above the statistical norm for any pharmaceutical product in history.
Three tiers. Three formulas. Distributed in a pattern that ensured no single hospital, no single city, no single demographic received enough catastrophic doses to trigger an obvious statistical signal.
They spread the damage thin enough to call it "rare side effects." But it wasn't rare. It was targeted.
⟁
The distribution pattern wasn't random. The catastrophic lots were sent disproportionately to specific zip codes. Zip codes with high concentrations of military veterans. First responders. Independent business owners. Communities with historically low compliance to federal mandates.
The people most likely to resist were given the most dangerous doses.
The moderate lots went to urban centers with high media consumption — populations that would report mild symptoms, be told it was "normal," and return for boosters without question.
The placebo lots went to politicians, media figures, and pharmaceutical executives. The people who promoted it on camera. The people who told you it was "safe and effective" while receiving saline.
They took the same shot on television. They did not take the same formula.
⟁
The 12,000 lot numbers are now mapped. Every batch. Every destination. Every outcome. The data is on the blockchain. It cannot be retracted. It cannot be memory-holed. It cannot be fact-checked into oblivion.
The former FDA regulator on the team submitted the dataset to the military tribunal with a single statement: "This was not negligence. This was a weapons deployment protocol disguised as public health."
The tribunal accepted it into evidence Thursday morning. Case number: GT-2026-0441.
Every lot number is a fingerprint. Every adverse event is a witness. Every death certificate is an indictment.
CODE: LOT-NUMBERS / 3-TIERS / ZIP-TARGETED / GT-2026-0441
They didn't give everyone the same shot. They gave everyone the shot they were assigned. Now the assignment list is evidence.
♟
Someone you know got a different formula than they were told. Share this for them.
Mr Pool
I'm often asked, "What percent of autism cases are caused by vaccines?" Now I have a precise estimate using the latest data and the standard epidemiological measure — Population Attributable Fraction. The answer is 75.6% to 79.6%.
https://t.co/bDwFpxULfX
The US Army already ran a clinical trial with an Andes strain hantavirus DNA gene-therapy injection — the exact same strain behind the cruise ship outbreak.
98% of participants suffered adverse events.
The DNA plasmid was created at the Fort Detrick BSL-4 army lab.